NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 11 மணி நேரத்திற்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Rubfila Re-Appoints Managing Director G. Krishna Kumar for a 3-Year Term
Rubfila International's Board of Directors has approved the re-appointment of Mr. G. Krishna Kumar as Managing Director for a term of three years, effective November 1, 2026. This follows the completion of his previous term on October 31, 2026, and remains subject to shareholder approval. The move provides leadership continuity for the Rs 323 Cr market cap company, which generated Rs 568 Cr in TTM revenue. Mr. Krishna Kumar is confirmed as not debarred from holding office by SEBI or any other regulatory authority.
உச்சம் நம்பிக்கை
என்ன மாறியதுMr. G. Krishna Kumar has been re-appointed as Managing Director for an additional 3-year term starting November 1, 2026.
ஏன் இது முக்கியம்Ensures leadership and executive continuity to oversee Rubfila's ongoing operations, latex thread utilization, and the Premier Tissues subsidiary expansion.
Re-appointment term: 3 yearsEffective date: 1 நவம்பர் 2026Previous term end date: 31 அக்டோபர் 2026
📅 குறுகிய காலம்Neutral procedural impact; business operations continue without leadership disruption.
📈 நீண்ட காலம்Maintains stability at the top executive level as the company navigates raw material volatility and tissue brand scaling.
⚠ அபாய எச்சரிக்கைகள்
Subject to shareholder approval
👀 கவனிக்க வேண்டியவை
Monitor voting results from the upcoming general meeting for formal shareholder ratification of the re-appointment.
Rubfila Q2 FY27 Standalone PAT at ₹5.04 Cr, Down 29.6% YoY; EPS at ₹0.93
Rubfila International reported its Q2 FY27 (period ended Sep 30, 2026) standalone financial results. Standalone net profit stood at ₹5.04 Cr (₹503.95 Lakhs), down 29.6% YoY from ₹7.16 Cr (₹715.99 Lakhs) in Q2 FY26, and down from ₹6.00 Cr in Q1 FY27. Diluted EPS for the quarter dropped to ₹0.93 from ₹1.32 in the year-ago period. A final dividend of ₹2.00 per share (₹10.85 Cr total) approved at the AGM was accounted for during the quarter.
உச்சம் நம்பிக்கை
என்ன மாறியதுRubfila announced its Q2 FY27 financial results showing a quarterly net profit decline of nearly 30% YoY on a standalone basis.
ஏன் இது முக்கியம்The earnings compression reflects continued margin pressure, likely from volatile natural latex prices, dampening TTM earnings trajectory.
Standalone PAT (Q2 FY27): ₹503.95 லட்சம்Standalone PAT (Q2 FY26): ₹715.99 லட்சம்Diluted EPS (Q2 FY27): ₹0.93Dividend Paid: ₹1,085.35 லட்சம்
📅 குறுகிய காலம்Negative earnings trajectory and an auditor-modified opinion could lead to subdued sentiment around the stock in the near term.
📈 நீண்ட காலம்Performance will hinge on the scale-up and margin contribution of subsidiary Premier Tissues alongside recovery in latex rubber thread operating margins.
⚠ அபாய எச்சரிக்கைகள்
Auditors issued a modified opinion on the financial results
YoY contraction in quarterly net profitability and EPS
High raw material latex price sensitivity
👀 கவனிக்க வேண்டியவை
Track the full text of the statutory auditors' modified opinion once detailed on exchanges, and monitor raw material latex cost pressures on consolidated margins in Q3.
Rubfila Shareholders Reject Divestment of Premier Tissues India with 68.01% Votes Against
Rubfila International has disclosed its 33rd AGM voting results, where shareholders decisively rejected the special resolution to ratify the divestment of its entire shareholding in subsidiary Premier Tissues India Limited. Out of 43,47,722 non-interested votes cast on the divestment resolution, 68.01% (29,56,734 votes) voted against, causing the proposal to fail. Meanwhile, ordinary resolutions including the adoption of FY26 financials and a final dividend of Rs 2.00 per share (40%) were approved with over 99.99% majority. The rejection halts the planned exit from the tissue business, which contributed Rs 46.05 Cr to H1 FY26 revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders blocked the company's proposed divestment of Premier Tissues India Limited at the AGM, while approving the dividend and regular business items.
ஏன் இது முக்கியம்Premier Tissues is a core growth driver contributing significantly to top-line (Rs 46.05 Cr in H1 FY26); the failed vote stalls the management's capital allocation and restructuring roadmap.
📅 குறுகிய காலம்Market may react with uncertainty around corporate strategy given the shareholder pushback on the asset sale.
📈 நீண்ட காலம்Rubfila retains its tissue paper business; management must decide whether to continue investing in Premier Tissues' expansion or propose revised exit terms.
⚠ அபாய எச்சரிக்கைகள்
Strategic uncertainty regarding capital allocation and future plans for Premier Tissues India
Shareholder-management misalignment on corporate restructuring
👀 கவனிக்க வேண்டியவை
Track management commentary in upcoming filings regarding their strategic path forward for Premier Tissues India, including whether they intend to retain the subsidiary or renegotiate divestment terms.
Rubfila Holds 33rd AGM; Proposes Divestment of Entire Stake in Premier Tissues India
Rubfila International concluded its 33rd Annual General Meeting on September 29, 2026, where shareholders considered ordinary and special resolutions. Crucially, special business included approval for the divestment of the company's entire shareholding in Premier Tissues India Limited, a subsidiary that contributed Rs 46.05 Cr in H1 FY26. Other items included adoption of FY26 financials and declaration of dividend. E-voting results under Regulation 44 will follow to confirm shareholder approval.
உச்சம் நம்பிக்கை
என்ன மாறியதுRubfila held its 33rd AGM and tabled a proposal to completely divest its equity stake in its operating subsidiary Premier Tissues India Limited.
ஏன் இது முக்கியம்Premier Tissues is a key revenue driver (Rs 46.05 Cr in H1 FY26, targeting 15-20% of consolidated sales). Selling it will refocus Rubfila entirely on its core rubber thread business and generate cash proceeds.
Total shareholders present at AGM: 44Premier Tissues H1 FY26 revenue contribution: Rs 46.05 கோடிPremier Tissues H1 revenue vs TTM revenue: ~8.1%Divestment consideration/valuation: வெளியிடப்படவில்லை
📅 குறுகிய காலம்Scrutinizer's voting report will be released within 48 hours to confirm whether the divestment resolution passed.
📈 நீண்ட காலம்Exiting the tissue business reverses Rubfila's recent diversification strategy, concentrating the company once again purely on heat-resistant latex rubber thread manufacturing and latex price cycles.
⚠ அபாய எச்சரிக்கைகள்
Loss of revenue diversification away from volatile latex raw material costs.
Divestment consideration, deal value, and buyer details not yet disclosed.
👀 கவனிக்க வேண்டியவை
Track the upcoming Regulation 44 voting results disclosure and subsequent announcements detailing the valuation, buyer, and cash consideration for the Premier Tissues divestment.
Rubfila Sets Sep 22, 2026 Record Date for Rs 2/Share Final Dividend (FY26)
Rubfila International has fixed September 22, 2026, as the record date to determine shareholder eligibility for a final dividend of Rs 2 per equity share (face value Rs 5) for FY26. The dividend was originally recommended at the Board meeting held on May 26, 2026. At the current share price of Rs 63.6, the Rs 2 per share dividend represents a dividend yield of approximately 3.14%.
உச்சம் நம்பிக்கை
என்ன மாறியதுFormal intimation of the record date (September 22, 2026) for the FY26 final dividend payout.
ஏன் இது முக்கியம்Confirms the timeline for distributing cash returns to shareholders, reflecting payout on FY26 EPS of Rs 4.89.
Final Dividend per share: Rs.2/-Face Value: Rs.5ரெக்கார்ட் தேதி: 22-09-2026Dividend to TTM EPS ratio: ~41.9%
📅 குறுகிய காலம்Stock will trade ex-dividend prior to September 22, 2026, typically adjusting downward by the dividend amount.
📈 நீண்ட காலம்Limited; reflects routine annual dividend distribution supported by zero debt and consistent profitability.
👀 கவனிக்க வேண்டியவை
Investors seeking dividend eligibility must hold shares before the ex-dividend date preceding September 22, 2026; track dispatch/credit timelines post-AGM approval.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Rubfila to divest 100% stake in Premier Tissues for ₹61.00 Cr to promoter-related entity
Rubfila International's Board has approved the complete divestment of its wholly owned subsidiary, Premier Tissues (India) Limited (PTIL), to Finquest Personal Care Pvt. Ltd. for an aggregate cash consideration of ₹61.00 crore. The transaction is a related-party deal, as the purchaser is associated with Rubfila's Chairman, Mr. Hardik Patel, who recused himself from deliberations. For FY26, PTIL contributed ₹95.74 crore (15.68%) to consolidated turnover and ₹51.49 crore (16.59%) to consolidated net worth. The deal consideration of ₹61.00 crore represents ~16.3% of Rubfila's current market cap (₹374 crore), allowing the company to refocus capital on its core rubber-thread business.
உச்சம் நம்பிக்கை
என்ன மாறியதுRubfila is fully divesting its tissue paper subsidiary PTIL for ₹61.00 crore to refocus entirely on its core rubber thread operations.
ஏன் இது முக்கியம்The sale relieves Rubfila of PTIL's upcoming capex requirements and brings in ₹61.00 crore in cash, but will reduce top-line by ~15.7% going forward.
Sale Consideration: ₹61.00 கோடிPTIL FY26 Revenue: ₹95.74 கோடிPTIL Revenue Share: 15.68%PTIL Net Worth Share: 16.59%Consideration vs M-Cap: ~16.3%
📅 குறுகிய காலம்Shareholder scrutiny is expected around the transaction terms and valuation multiples since the divestment is to a promoter-linked entity.
📈 நீண்ட காலம்Unwinds non-core diversification, boosting Rubfila's cash balances and sharpening managerial focus on the heat-resistant latex rubber thread segment.
⚠ அபாய எச்சரிக்கைகள்
Related-party transaction involving the Chairman/promoter entity requiring minority shareholder approval
Loss of diversification benefits as PTIL accounted for ~15.7% of consolidated revenue
👀 கவனிக்க வேண்டியவை
Track minority shareholder voting outcomes on the related-party transaction at the upcoming AGM on September 29, 2026, and watch for subsequent cash inflow updates and deployment plans for the core business.
Rubfila Q1 FY27 PAT Falls 13% YoY to ₹5.8 Cr; Auditor Flags ₹13.8 Cr Contingency Provision
Rubfila International reported a weak start to FY27 with consolidated revenue declining 7.9% YoY to ₹133.49 Cr. Net profit followed suit, dropping 13.3% YoY to ₹5.80 Cr, primarily due to a 12.8% decline in standalone revenue. A significant highlight is the auditor's qualified opinion regarding a ₹13.79 Cr 'Provision for Contingencies' accumulated over 11 years, which the auditors claim does not meet Ind AS 37 criteria for recognition. The tissue subsidiary, Premier Tissues, contributed ₹24.45 Cr to the topline but remains marginally loss-making at the PAT level.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company experienced a YoY contraction in both revenue and profit, while the statutory auditors formally challenged the validity of a long-standing ₹13.79 Cr contingency provision.
ஏன் இது முக்கியம்The decline in standalone revenue suggests potential demand or pricing headwinds in the core rubber thread market, while the auditor qualification points to non-standard accounting practices that impact the transparency of the balance sheet.
📅 குறுகிய காலம்The stock may face pressure due to the double-digit profit decline and the negative auditor remarks regarding accounting compliance.
📈 நீண்ட காலம்Long-term value depends on the successful integration and scaling of the tissue business and the company's ability to maintain margins in the rubber thread segment despite volatile latex prices.
⚠ அபாய எச்சரிக்கைகள்
Auditor qualification on Ind AS 37 compliance
Loss-making subsidiary operations
Declining standalone revenue growth
👀 கவனிக்க வேண்டியவை
Investors should monitor the turnaround progress of the tissue subsidiary and watch for management's response to the auditor's qualification regarding the contingency provision, which currently understates equity by ₹13.79 Cr.
Rubfila International reported a steady performance for FY26 with consolidated revenue reaching ₹60,249.96 Lakhs, up from ₹55,041.28 Lakhs in the previous year. However, consolidated net profit for the full year saw a decline to ₹2,661.19 Lakhs compared to ₹2,943.85 Lakhs in FY25, indicating margin pressure at the group level. Standalone performance was more resilient, with annual net profit rising to ₹2,630.13 Lakhs. The company has rewarded shareholders by recommending a dividend of ₹2.00 per equity share (40% of face value).
முக்கிய அம்சங்கள்
Consolidated annual revenue increased by 9.5% YoY to ₹60,249.96 Lakhs.Consolidated net profit for FY26 declined to ₹2,661.19 Lakhs from ₹2,943.85 Lakhs in FY25.Standalone Q4 net profit rose to ₹824.63 Lakhs from ₹768.51 Lakhs in the corresponding quarter of the previous year.The Board recommended a dividend of ₹2.00 per equity share of face value ₹5/-.Consolidated Earnings Per Share (EPS) for the full year stood at ₹5.03, down from ₹5.51 in the previous fiscal year.
👀 கவனிக்க வேண்டியவை
Investors should monitor the divergence between standalone and consolidated profitability, which suggests underperformance in subsidiaries. The stock remains a hold for dividend-seeking investors given the ₹2 payout.
Rubfila International FY26 Revenue Up 9.5% to ₹602 Cr; Recommends ₹2 Dividend
Rubfila International reported a consolidated revenue growth of 9.5% year-on-year, reaching ₹602.50 crore for the fiscal year ended March 31, 2026. However, consolidated net profit saw a decline of 9.6%, falling to ₹26.61 crore from ₹29.44 crore in the previous year, indicating margin pressure. On a standalone basis, the company performed better with a net profit of ₹26.30 crore compared to ₹24.65 crore in FY25. The Board has recommended a dividend of ₹2.00 per equity share, representing a 40% payout on the face value of ₹5.
முக்கிய அம்சங்கள்
Consolidated annual revenue increased to ₹602.50 crore in FY26 from ₹550.41 crore in FY25.Consolidated net profit for the year declined to ₹26.61 crore vs ₹29.44 crore YoY.Standalone Q4 FY26 revenue stood at ₹138.51 crore with a profit of ₹8.25 crore.Recommended a final dividend of ₹2.00 per equity share for FY26.Consolidated Earnings Per Share (EPS) decreased to ₹5.03 from ₹5.51 in the previous fiscal.
👀 கவனிக்க வேண்டியவை
Investors should note the steady standalone performance but investigate the drag on consolidated profits caused by subsidiaries. The dividend yield remains a positive factor, but margin sustainability in the rubber filaments business needs to be monitored.
Rubfila Q3 FY26 Consolidated Net Profit Drops 31% YoY to ₹5.50 Crore
Rubfila International reported a consolidated revenue of ₹146.73 crore for the quarter ended December 31, 2025, a 6.3% increase year-on-year but a 2.3% decline sequentially. Profitability was significantly impacted, with consolidated net profit falling 30.9% YoY to ₹5.50 crore from ₹7.96 crore. This decline is attributed to rising operational costs, with total expenses increasing to ₹140.94 crore. Standalone performance also weakened, with net profit dropping to ₹4.93 crore compared to ₹6.57 crore in the year-ago period.
முக்கிய அம்சங்கள்
Consolidated Revenue from Operations rose 6.3% YoY to ₹146.73 crore.Consolidated Net Profit declined sharply by 30.9% YoY to ₹5.50 crore.Earnings Per Share (EPS) decreased to ₹1.01 from ₹1.47 in the same quarter last year.Total Consolidated Expenses increased to ₹140.94 crore from ₹128.85 crore YoY.Nine-month consolidated net profit stands at ₹20.19 crore, down from ₹21.13 crore in the previous year.
👀 கவனிக்க வேண்டியவை
Investors should be cautious as the sharp decline in margins suggests rising input costs or operational inefficiencies that are outpacing revenue growth. Monitor the company's ability to pass on costs in upcoming quarters before making new positions.
Rubfila Q3 FY26 Standalone PAT Drops 24.8% YoY to ₹4.93 Cr Despite Revenue Growth
Rubfila International reported a weak bottom-line performance for Q3 FY26, with standalone Net Profit falling 24.8% YoY to ₹4.93 crore. While standalone revenue saw a modest growth of 3.8% YoY to ₹121.61 crore, it declined 5.1% on a sequential basis compared to Q2 FY26. Profitability was significantly impacted by rising operational costs, leading to a drop in EPS from ₹1.21 to ₹0.91. On a consolidated basis, the profit decline was even steeper at 30.8% YoY, indicating pressure across the group's operations.
முக்கிய அம்சங்கள்
Standalone Revenue from Operations increased 3.8% YoY to ₹12,161.10 lakhs.Standalone Net Profit (PAT) declined 24.8% YoY to ₹493.39 lakhs from ₹656.58 lakhs.Consolidated Q3 PAT fell sharply by 30.8% YoY to ₹550.32 lakhs.Standalone EPS for the quarter stood at ₹0.91, down from ₹1.21 in the same period last year.Total standalone expenses for the quarter rose to ₹11,634.69 lakhs compared to ₹10,966.70 lakhs YoY.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's margin profile closely as rising costs are eroding profitability despite stable revenues. The sequential decline in both revenue and profit suggests a challenging near-term environment for the rubber filament segment.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
